enGene Holdings Inc. Common Stock (ENGN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, enGene Holdings Inc. Common Stock (ENGN) has a cash flow conversion efficiency ratio of -0.103x as of January 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-28.90 Million) by net assets ($281.55 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
enGene Holdings Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how enGene Holdings Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read ENGN liabilities breakdown for a breakdown of total debt and financial obligations.
enGene Holdings Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of enGene Holdings Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Community Healthcare Trust Inc
NYSE:CHCT
|
0.036x |
|
DONGGUAN R.COMMERC. H YC1
F:857
|
N/A |
|
Lyell Immunopharma Inc
NASDAQ:LYEL
|
-0.130x |
|
Daesang Corp
KO:001680
|
0.093x |
|
Regal Investment Fund
AU:RF1
|
0.039x |
|
Fulcrum Therapeutics Inc
NASDAQ:FULC
|
-0.072x |
|
Bloomin Brands Inc
NASDAQ:BLMN
|
0.353x |
|
Qingdao Greensum Ecology Co. Ltd.
SHE:300948
|
N/A |
Annual Cash Flow Conversion Efficiency for enGene Holdings Inc. Common Stock (2021–2025)
The table below shows the annual cash flow conversion efficiency of enGene Holdings Inc. Common Stock from 2021 to 2025. For the full company profile with market capitalisation and key ratios, see market value of enGene Holdings Inc. Common Stock.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-10-31 | $167.71 Million | $-99.24 Million | -0.592x | -234.11% |
| 2024-10-31 | $272.61 Million | $-48.28 Million | -0.177x | +48.12% |
| 2023-10-31 | $72.49 Million | $-24.74 Million | -0.341x | -147.25% |
| 2022-10-31 | $127.42 Million | $-17.59 Million | -0.138x | -10.03% |
| 2021-10-31 | $127.39 Million | $-15.98 Million | -0.125x | -- |
About enGene Holdings Inc. Common Stock
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. enGen… Read more